Understanding how genetic changes in bladder cancer affect treatment resistance
Targeting APOBEC3A-induced genetic heterogeneity and drug resistance in bladder cancer
This study is looking at how a protein called APOBEC3A affects the way bladder cancer cells change and become resistant to treatments, with the goal of finding better ways to target these tough cancer cells and improve outcomes for patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10932366 on NIH RePORTER |
What this research studies
This research investigates the role of a specific protein, APOBEC3A, in causing genetic diversity within bladder cancer cells, which can lead to resistance against treatments. By examining how this protein contributes to the emergence of resistant cancer cell subclones, the research aims to identify new strategies to target these vulnerabilities. The approach includes studying patient-derived organoids and cell lines to uncover the mechanisms behind this resistance and develop precision therapies that could improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced urothelial carcinoma who are experiencing treatment resistance.
Not a fit: Patients with early-stage bladder cancer or those who do not have urothelial carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for bladder cancer patients by overcoming drug resistance.
How similar studies have performed: Previous research has shown promising results in targeting genetic heterogeneity in cancers, suggesting that this approach could be effective.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Faltas, Bishoy Morris — Weill Medical Coll of Cornell Univ
- Study coordinator: Faltas, Bishoy Morris
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.